Digital PCR (dPCR) is a highly accurate molecular technology that is used by dividing nucleic acid (DNA or RNA) into thousands of individual reactions, which allows absolute prohibition without the requirement of standard curves. It provides more sensitivity, accuracy and copy-replicated ability than traditional PCR, which is ideal for detecting low-objective goals, rare mutation and copy number variations. Digital PCR market growth is inspired by early and accurate disease diagnosis, increasing applications in cancer and infectious disease research, progress in personal medicine, and increasing demand for increasing demand for the increasing requirement of accurate genetic testing in clinical and research settings.
Key Growth Drivers and Opportunities
Increasing Applications in Cancer and Infectious Disease Research: The growing application of digital PCR in cancer and infectious disease research is the leading drivers of market development, as technology provides highly sensitive and accurate identity of rare variants. In cancer research, digital PCR tumor markers, minimal residual disease, and the exact amount of circulating tumor DNA (CTDNA) supports the stagnation, initial diagnosis, treatment monitoring and personal therapy. Similarly, in infectious disease research, it allows rapid and reliable detection of viral and bacterial pathogens in low viral load cases. This ability to give high-resolution data with minimal error makes digital PCR an essential tool in modern biomedical research, which enhances its adoption and expansion in the global market.
Challenges
Digital PCR market faces several limitations including high means and operating costs, which can obstruct adoption in small laboratories and resource-limit settings. Technology also has a relatively low throughput compared to quantitative PCR, making it less suitable for mass screening. Additionally, limited standardization in platforms and protocols can affect breeding and result interpretation. Lack of skilled personnel and the need for advanced data analysis equipment is challenged more comprehensive implementation, especially in clinical settings. These factors collectively prevent the full market capacity of digital PCR despite their better sensitivity and accuracy.
Innovation and Expansion
The First Ultrasensitive Multiplex Digital PCR Assay for Breast Cancer Research Is Released by Bio-Rad
In April 2024, A world leader in clinical diagnostics and life science research, Bio-Rad Laboratories, Inc., recently unveiled the ddPLEX ESR1 Mutation Detection Kit, its first ultrasensitive multiplexed digital PCR test. The assay broadens the company’s Droplet Digital PCR (ddPCR) product line for the cancer industry, where multiplexed mutation detection assays with high sensitivity support medication selection, translational research, and disease monitoring.
With an analytical sensitivity as low as 0.01% variable allele fraction (VAF), the ddPLEX ESR1 Mutation Detection Kit allows for the simultaneous detection, discrimination, and absolute quantification of seven known important ESR1 mutations in a single well. The kit allows for same-day findings from either DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples or circulating tumor DNA (ctDNA) from plasma. It also includes controls.
The World’s First Six-Color Digital PCR System was Unveiled by Stilla Technologies
In June 2020, the world’s first six-color digital PCR equipment, the six-color Prism, was introduced by Stilla Technologies, a top supplier of digital PCR (dPCR) solutions for high-precision genetic analysis. The device increases the Naica System, the company’s digital PCR platform,’s multiplexing capabilities.
The tool has been approved for use in the detection and measurement of genetically modified organisms in the food chain, liquid biopsy monitoring in breast and rectal cancer, and EGFR mutation quantification using a six-color lung cancer panel. Oncology, infectious illness, gene therapy, disease monitoring, and food testing are among the fields that use the six-color prism.
Inventive Sparks, Expanding Markets
The key players operating the digital PCR market includes, Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd., Bio-Rad Laboratories Inc., Merck KGaA, Stilla Technologies, QIAGEN, JN Medsys, Avance Biosciences, Snibe Co. Ltd., Standard BioTools Inc., and others.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
